Evidence map›Paper›PMID 34788110›Full record

Observational studyAIDS patient care and STDs2021

Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis.

Lentlametse Mantshonyane, Jason Roy, Michael Z Levy, Carole L Wallis, Kathrine Bar, Catherine Godfrey, Ann Collier, Alberto LaRosa, Lu Zheng, Xin Sun and 1 more

Abstract readObservational Study
In one paragraph

Observational study in AIDS patient care and STDs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lentlametse MantshonyaneBotswana University of Pennsylvania Partnership, Gaborone, Botswana.ORCID 0000-0002-5785-6809
Jason RoyDepartment of Biostatistics and Epidemiology, Rutgers University, New Brunswick, New Jersey, USA.
Michael Z LevyDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Carole L WallisMolecular Division, BARC-SA and Lancet Laboratories, Johannesburg, South Africa.
Kathrine BarMolecular Division, BARC-SA and Lancet Laboratories, Johannesburg, South Africa.
Catherine GodfreyOffice of the Global AIDS Coordinator, US Department of State, Philadelphia, Pennsylvania, USA.
Ann CollierDivision of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, Washington, USA.
Alberto LaRosaAsociación Civil Impacta Salud y Educación, Lima, Perú.
Lu ZhengDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Xin SunDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Robert GrossDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Penn Mental Health AIDS Research CenterP30MH097488 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Karine Dube · 2013 to 2026
$23.5M
HIV Research Training Program for BotswanaD43TW009781 · FIC · UNIVERSITY OF PENNSYLVANIA · PI GROSS, ROBERT · 2014 to 2018
$1.7M
FIC NIH HHS D43 TW009781NIAID NIH HHS P30 AI045008NIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069463NIMH NIH HHS P30 MH097488
6 · The paper itself

Abstract

Evidence on the impact of human immunodeficiency virus (HIV) drug resistance on regimens following treatment failure is varied and inconclusive. Differential medication adherence may explain this variation. We aimed to test the association between drug resistance at first-line antiretroviral therapy (ART) switch and adherence to and virologic failure on subsequent ART. We conducted a secondary analysis of data from an open-labeled randomized trial of second-line ART (ACTG A5234). ART susceptibility was determined from study entry plasma using the Stanford Drug Resistance database version 8.7. Adherence was measured with microelectronic monitors. Three adherence variables and rates of virologic failure (HIV-1 RNA ≥1000 copies/mL) on second-line ART were compared between participants with and without resistance at first-line ART failure. Of 214 participants switching to second-line ART with baseline resistance results, 113 (53%) were men, mean age was 39 years (standard deviation 10.3), and 37 (17%) had susceptible virus at study entry. Cumulative genotypic susceptibility score (cGSS) was inversely associated with adherence, adjusted odds ratio (aOR) 0.15, 95% confidence interval (CI) (0.05-0.40),

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveHumansMaleTreatment FailureViral LoadAnti-HIV AgentsAnti-Retroviral AgentsAIDSantiretroviral therapy (ART)drug resistancegenotypic susceptibility scorehuman immunodeficiency virusvirologic failurewild-type virus

Identifiers

PMID34788110
PMCPMC8905302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.